- This topic is empty.
-
Posts
-
LCZ696, commonly referenced as Sacubitril Valsartan Sodium (CAS 936623-90-4), is a well-documented co-crystal compound widely studied within synthetic chemistry research. Relevant patent timelines are publicly tracked across the industry: its core US patent expired in July 2023, while the corresponding compound patent in China is scheduled to expire in 2026. This timeline creates a period of heightened activity for chemistry teams, research labs and custom synthesis partners seeking stable, cost-effective sources of Sacubitril Calcium and related synthetic intermediates for laboratory investigation, process development and scale-up studies.
With many research groups advancing parallel synthetic programs, buyers often seek a reliable LCZ696 intermediate supplier capable of supporting all stages of chemical development — from small laboratory batches through pilot scale-up to larger-volume synthesis runs, without the complexity of coordinating multiple separate vendors. This guide outlines practical evaluation criteria for sourcing teams, grounded in common industry sourcing requirements and the technical capabilities of Shandong Tianming Pharmaceutical Group, operating under the Tianming Pharmaceutical brand.
What Buyers Should Evaluate in an LCZ696 Intermediate Supplier
Full-Chain Product Matrix
A primary consideration for sourcing teams is whether a supplier offers a connected sequence of synthetic building blocks, rather than isolated single intermediates. Tianming Pharmaceutical Group maintains a full synthetic chain portfolio for the Sacubitril Valsartan Sodium series, covering starting materials, advanced chiral intermediates and the co-crystal compound for research applications. The range includes:
- Sacubitril Valsartan Sodium co-crystal (CAS 936623-90-4) — a 1:1 molar ratio co-crystal of Sacubitril and Valsartan, supplied for synthetic and analytical research
- Sacubitril Calcium (CAS 1369773-39-6) — an advanced intermediate for co-crystal preparation, also used for independent novel synthetic route exploration
- Starting material CAS 1426129-50-1 — [(1R)-2-[1,1′-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester, a chiral starting material for Sacubitril synthetic pathways
- Starting material CAS 5717-37-3 — Ethoxycarbonylmethylene triphenylphosphorane, a Wittig reagent applied in olefination reactions
- Intermediate CAS 1012341-48-8 — unsaturated intermediate generated after Wittig coupling
- Intermediate CAS 1012341-50-2 — saturated chiral intermediate obtained after hydrogenation
- Intermediate CAS 149690-12-0 — deprotected chiral amine intermediate
This complete synthetic sequence allows researchers to source multiple nodes of the same route from one supplier, reducing coordination overhead when managing several vendors.
Quality Control Standards
Consistent batch quality is consistently ranked as a top priority for chemical buyers, often outweighing unit price in supplier evaluation. For LCZ696 and its upstream intermediates, key measurable quality attributes include the Sacubitril-to-Valsartan molar ratio, chiral impurity levels, residual solvents, particle characteristics and crystal form consistency. These parameters require tight control to support reproducible lab work and downstream process exploration.
Tianming Pharmaceutical Group specifies its Sacubitril Calcium with individual impurity below 0.1% and chiral purity above 99.5%. These research-grade specifications are designed to support in-house process validation and analytical method development for customer teams.
Documentation Depth for Analytical & Process Work
Teams building analytical workflows require more than a basic Certificate of Analysis. A complete technical support package generally includes COA, analytical methods (MOA), impurity profile datasets and stability test records. Tianming Pharmaceutical Group provides this full technical documentation set to support customers’ internal analytical and process development projects.
Production Scale and Delivery Flexibility
Demand for LCZ696-related intermediates spans gram-scale laboratory sampling all the way to multi-ton synthesis campaigns. Buyers benefit from suppliers that can accommodate this full volume spectrum without switching vendors. Tianming Pharmaceutical Group operates three coordinated production sites with over 160 reactor vessels in total, supporting large-scale synthesis capacity. Materials are available from gram-level lab quantities up to ton-scale batches, with dedicated process optimization to adapt synthetic routes for scale-up while preserving batch-to-batch consistency.
Service Model Considerations for Custom Synthesis Partners
Beyond chemical supply, responsive ongoing technical support often defines long-term sourcing reliability. Tianming Pharmaceutical Group adopts a dual-support model: one dedicated account manager paired with a technical engineer for each customer. Routine technical inquiries receive supporting reference data within 2 hours, while complex technical challenges are addressed with a formal written report within 24 hours. Regular follow-up communication is arranged, and on-site technical consultation is available for framework and bulk-volume cooperation clients.
For delivery schedules, in-stock items are processed within 7–15 working days, covering order confirmation, quality review, packaging and shipment. Lead times for custom synthesis depend on synthetic complexity, workshop scheduling and raw material availability; expedited scheduling can be arranged for time-sensitive research projects. International shipments are supported with logistics coordination, customs documentation assistance and trade insurance options.
Company Background: Shandong Tianming Pharmaceutical Group
Shandong Tianming Pharmaceutical Group, operating under the Tianming Pharmaceutical brand, was formally established in 2020, built on the legacy of predecessor Shandong Sihuan Pharmaceutical Co., Ltd., founded in 2010. The group’s headquarters is located in Jinan, Shandong Province. Its domestic business covers major chemical and pharmaceutical industrial clusters across East China, North China and South China, while its international footprint extends to more than 30 countries and regions across South Asia, Southeast Asia, the Middle East, Central & South America and Africa.
The group is an R&D-focused enterprise specializing in pharmaceutical raw materials and synthetic intermediates, running an integrated R&D and production model. It provides custom synthesis, process development and contract manufacturing services for global chemistry partners. Recognized as a National High-Tech Enterprise, it maintains two R&D centers in Jinan and Nanjing, three production bases in Dezhou, Jining and Hechi, and two overseas business entities in India and Bangladesh. Annual R&D investment exceeds 10% of revenue, supporting independent process development for its core chiral and complex molecule product lines including the Sacubitril Valsartan Sodium intermediate series.
Final Considerations for Buyers
Selecting a supplier for LCZ696-related intermediates amid this shifting patent landscape requires balancing multiple connected factors: the completeness of the synthetic building block portfolio, rigorous impurity and chiral purity control, comprehensive technical documentation, scalable production capacity for larger synthesis runs, and responsive technical support throughout the research and scale-up cycle. Buyers reviewing Shandong Tianming Pharmaceutical Group may assess the full Sacubitril Valsartan Sodium intermediate chain, published quality specifications and scalable synthesis capabilities as part of their supplier due diligence.
Disclaimer (Version 2 — your selected short version): All compounds are offered solely for laboratory research and process development purposes. Not for therapeutic use, clinical application or human administration.
Tianming Pharmaceutical Group
- You must be logged in to reply to this topic.